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Abstract: Palatability is a recognized driver of medicine acceptability in pediatrics but deemed less
relevant in older populations due to sensory decline. Preliminary findings from an observational
study implicated palatability problems with one Alzheimer’s medicine. Among 1517 observer reports
combining multiple measures on medicines uses in patients aged over 64, we focused on two original
formulations of memantine (Ebixa®, tablets (n = 25) and oral solution (n = 60)). Evaluations were
scored with an acceptability reference framework (CAST), the rodent Brief Access Taste Aversion
(BATA) model tested aversiveness. Focusing on women treated with Ebixa® (n = 54), the oral
formulation sub-group was classified as “negatively accepted”, while the coated tablet was associated
with the “positively accepted” cluster. In men, both formulations belonged to the “positively accepted”
profile. Using BATA, the original oral solution was categorized as highly aversive/untolerated while
solutions of excipients only were well tolerated. Furthermore, the number of licks was significantly
lower in female than in male rats. These results revealed that medicine palatability remains important
for acceptability in older populations. Moreover, converging results from humans and animal models
highlighted that palatability profiles can significantly vary between the sexes. These drivers should
be closely considered during drug development to enhance acceptability in this population.
Keywords: medicine; acceptability; palatability; taste assessment; older population; formulation;
Alzheimer; sex; CAST—clinsearch acceptability score test; brief-access taste aversion
1. Introduction
Adherence is crucial for obtaining optimum clinical benefits from any treatment. In the past decade,
the World Health Organization (WHO) has devoted a full report to this concept [1] in which adherence
to long-term therapy was reported to average only 50% in developed countries. The WHO report
emphasized that this resulted in poorer outcomes while increasing health care costs. According to a
systematic review [2], in the United States lack of adherence was estimated to have led to approximately
125,000 deaths and at least 10% of all hospitalizations annually. The authors also stated that the cost to
the US healthcare system of non-adherence has been estimated between $100 billion and $289 billion per
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year. In 2018, the Organisation for Economic Co-operation and Development (OECD) addressed this
subject in a working paper entitled “Investing in medication adherence improves outcomes and health
system efficiency”. Based on data from across Europe in 2010, the OECD estimated that poor adherence
to treatment led to nearly 200,000 premature deaths, and in terms of avoidable hospitalizations alone
was responsible for 125 billion euros of government spending annually [3].
In this context, the European Medicine Agency (EMA) came to consider that patient acceptability
is likely to have a significant impact on patient adherence and consequently on the safety and efficacy of
medicinal products. Acceptability has been defined by the EMA as “The overall ability and willingness
of the patient to use and its care giver to administer the medicine as intended”. To encourage
developers to consider medicine acceptability for pediatric patients, the EMA dedicated a chapter to
this multi-faceted concept in a recent guideline [4]. Key drivers of acceptability from product and
patient characteristics were identified, palatability (and swallowability) was (were) first on the EMA’s
list of product characteristics. Indeed, as many drugs have a bitter and often aversive taste, this poses
a challenge to the development of palatable oral dosage forms [5]. However, when the EMA drafted a
comparable reflection paper for the older population 3 years later, palatability was not addressed.
The epidemiology of diseases in the older population could support this omission of palatability
from the list of important product characteristics for acceptability in the older population: the prevalence
of dysgeusia increases with age [6–8]. However, as dysphagia is also a common disability in the
older population, the use of oral drug delivery may be compromised with age [9]. In practice, liquid
formulations have been developed for the older population to improve swallowability, but palatability
has generally not been taken into consideration.
An Alzheimer’s disease treatment, memantine hydrochloride, exemplified this formulation
strategy for older adults. The original medicine (Ebixa®, memantine hydrochloride) was formulated
as both a coated tablet (10 and 20 mg) and an oral solution (10 mg/mL). Surprisingly, the oral solution
was formulated without any flavoring agent [3].
Herein we have presented data contradicting these assumptions. Preliminary findings from
an observational study on medicines acceptability in the older population demonstrated that the
palatability of oral liquid pharmaceutical products remains a crucial acceptability driver, especially in
older women (unpublished observations).
To confirm these results and limit the bias induced by variation of product characteristics we
decided to focus our investigations on the two formulations of memantine hydrochloride cited above.
The data collected during an acceptability study in older adults has been combined with results from
an aversiveness study in animals to better understand the possible effects of sex and excipients.
2. Materials and Methods
2.1. Acceptability Study in Older Adults
2.1.1. Data Source
The data presented here were collected in a multicenter, prospective, cross-sectional and strictly
observational study conducted in France between October 2016 and May 2019. Patients were recruited
at random on a voluntary basis at the recruiting centers. Approvals (CCTIRS n◦16.390bis 12-SEP-2016)
were obtained from the French advisory committee for data processing in health research and the data
protection authority. Data collection was carried out in collaboration with a network of physicians and
pharmacists in eight hospitals and eight nursing homes. The healthcare professional observing the
first medicine use in older patients (65 years and over) following study inclusion, with the exception of
infusions in which a catheter was already present, filled in a standardized web-questionnaire consisting
of variables that explain and describe acceptability [10].
Healthcare professionals or clinical research associate reported information on the patient (e.g., sex,
age, comorbidities), the treatment (e.g., the pharmaceutical product taken, the required dose), and the
context of use (e.g., the person(s) in charge of preparing and administrating the medicine, the place and
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the time of medicine use) to investigate their influence on acceptability. Such information was generally
taken from the patient’s medical record. In addition, observers were required to report multiple
behaviors and events observed during the use of the medicine: the result of intake (the required dose
fully, partly or not taken at all), the patient reaction during the administration (positive, neutral or
negative reaction), the time needed to prepare (from opening any packaging to having a required
dose of medication ready to use, including all handling and modifications), and the time needed to
administer the required dose of medication (from a required dose of medication ready to use to the end
of its intake). Preparation and administration time were classified as short (less than 20 s), medium
(from 21 s to 1 min) or long (longer than 1 min). Furthermore, recourse to any methods to ease/achieve
administration was reported: dividing the intake of a dose which cannot be taken as a whole, altering
the intended use (manipulating dosage forms such as crushing tablets or opening capsules; use of a
device not provided; use of another route/mode of administration), use of food/drink to mask a taste or
ease swallowing, and use of restraint.
2.1.2. Data Analysis
To study medicine acceptability we used CAST—ClinSearch Acceptability Score Test® (CAST),
a data driven approach [11] with a dedicated tool for the older population [10].
To build the acceptability reference framework, all the observed measures were included in
the multivariate analysis without any weighting. A multiple correspondence analysis provided
a three-dimensional acceptability map summarizing the key relationships between the observed
measures. Subsequently, hierarchical clustering on principal components and k-means consolidation
gathered the most similar evaluations into two clusters, defining coherent acceptability profiles:
the “Positively accepted” and the “Negatively accepted” profiles. These profiles were materialized by
a green and a red area on the acceptability map, respectively.
Herein we used the reference framework to score the acceptability of the drug products of interest:
the original formulations of memantine hydrochloride (Ebixa®). The barycenter of the evaluations
related to each formulation (coated tablet and oral solution) defined its position on the map. Similarly,
we positioned on the map each formulation according to the sex of the patients (men vs. women).
A barycenter, along with the entire 90% confidence ellipsis surrounding it, belonging to the first
cluster defining the “Positively accepted” profile could be classified as such. A minimum of 30
evaluations were needed to produce an acceptability score, below this threshold an acceptability
tendency could be described. Acceptability could be considered as significantly different if confidence
ellipses surrounding two distinct barycenters did not overlap on the map.
Statistical tests were used to assess the significance of the differences observed between the
subpopulations of patients in term of age, sex, and disabilities. Pearson’s Chi-squared test was used
when there was a minimum expectation of five for 80% of cells without any null expectation [12].
When there were fewer observations, Fisher’s exact test was used.
The R packages “FactoMineR” [13] and “MissMDA” [14] were used to perform multivariate
analysis and to handle missing data, respectively (RStudio Version 1.0.136).
2.2. Aversiveness Study in Animals
The rodent Brief Access Taste Aversion (BATA) model detects objectively the aversive taste
of active pharmaceutical ingredients (API) [15–18]. This model, usable at an early stage of drug
development, seems quite predictive of human taste assessments [19]. It utilizes a lickometer which
records the number of licks that rodents (placed in an intermittent water-restriction schedule) take of
different test solutions in a standardized protocol [3].
2.2.1. Test Solutions
The original oral solution of memantine (Ebixa®) consisted of memantine hydrochloride at a
concentration of 10 mg/mL. Sorbitol is present as a sweetener agent, as well as potassium sorbate
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as a preservative, dissolved in purified water. The oral solution of memantine was assessed in its
unadulterated form as it would be administered to patients, and as 3-, 9-, and 27-fold dilutions in
deionised water, to examine any potential concentration effect.
The precise quantitative composition of excipients in the original memantine oral solution was
unknown. Therefore, solutions of excipients alone—potassium sorbate and sorbitol—were also
assessed and are referred to as “placebo” from here on despite not being the strict placebo. Potassium
sorbate (0.192% w/v) and sorbitol (10% w/v) were thus tested as drug free controls, along with 3- and
9-fold dilutions (in deionised water) of these solutions.
2.2.2. Data Collection
All procedures were carried out in accordance with the Animals (Scientific Procedures) Act 1986
(Project Licence PPL 70/7668), following the experimental method described hereafter.
Ten adult males and 10 adult females Sprague-Dawley rats (Charles-River, Kent, UK) aged 8 weeks
old were housed in pairs (same sex) in standard cages in a room that was maintained at 21 ± 2 ◦C with
55% ± 10% humidity and with a 12:12 h light/dark cycle. All training and testing occurred during the
light phase of the cycle. Animals had free access to chow (Harlan, Oxon, UK) and tap water except for
training and testing periods where a water-restriction schedule occurred. Each rat was water-deprived
for 22 h before each session (training and testing) and was then placed with the lickometer (“Davis
MS-160” lickometer from DiLog Instruments—Tallahassee, FL, USA) for a maximum session-length of
40 min. After each session, the rodents received tap water for rehydration. As a safety and welfare
measure each animal’s weight was monitored to ensure that it did not drop below 85% of their free
feeding weight.
The initial days of the protocol were dedicated to training: on the first training day, the shutter
was continually open, presenting a single tube containing deionised water to acclimatize the rodent to
the lickometer; while on the second training day, 16 tubes containing deionised water were presented
on the moving rack with the shutter opening/closing to acclimatize the rodent to the associated noise.
The training was followed by two testing days during which each rat was presented with various
sipper tubes containing either deionised water or one of the test preparations. The samples were both
presented at random and arranged at random on the Davis Rig (Table S1). The trial began when the rat
took its first lick from the sipper tube and ended 8 s later when the shutter closed. Each concentration
was presented four times per session (two bottles per test solution, two presentations per bottle).
2.2.3. Data Analysis
We followed the statistical analysis proposed by Soto et al. [20], as described briefly hereafter.
As the data were non-parametric (confirmed by the Shapiro–Wilk test of normality), the Kruskal–Wallis
test was performed to check for significant differences in the “lick numbers” between the different test
preparations. When significant, this analysis was followed by a post-hoc analysis carried out with the
non-parametric multiple test of Gao et al. to determine which test solutions were significantly different.
The percentage of inhibition of licks (/8 s) compared to a reference (i.e., deionised water or placebo
formulations) was calculated according to this equation:
% inhibition o f licks =
N0 licksre f erence − N0 licksconcentration API
N0 licksre f erence
× 100.
The R package “nparcomp” was used to compute the simultaneous p-values.
Test solutions were classified as fully tolerated, when there is no significant difference compared
to the negative control; well tolerated, when licks are significantly suppressed with respect to
the control but lick inhibition is lower than 30%; tolerated, when the lick inhibition between
31%–50%; aversive/untolerated, when the lick inhibition is in the range of 51%–75% and; highly
aversive/untolerated, when the lick inhibition is greater than 75% [20].
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3. Results
3.1. Acceptability Study in Older Adults
3.1.1. Patient Characteristics
Among the 1517 evaluations included in the multivariate analysis that gave rise to the final
acceptability reference framework, 390 (26%) defined the cluster “negatively accepted” (Tables S2
and S3 summarize the characteristics of the patients and the products included in the core study,
respectively). The original formulations of memantine were evaluated therein for 85 patients in hospital.
The mean age of these patients was 85 (6.6), the minimum age was 70, the maximum was 99, and 63.5%
were women.
There were 25 patients treated with the coated tablet (88% receiving 20 mg tablets and 12%
receiving 10 mg tablets), while the remaining 60 received the oral solution. The tablets are elliptical
varying in length from 10.5 mm (10 mg) to 13.1 mm (20 mg). There were no significant differences
between these groups of patients in terms of sex (p = 0.85), age group (p = 0.33), medicine exposure
(p = 1), cognitive impairment (p = 1), muscular or rheumatologic disorders of the upper limbs (p = 1),
and swallowing disorder (p = 0.72). Polypharmacy—≥10 different pharmaceutical drug products
per day—was significantly higher in the patients treated by tablet than in those treated with the oral
solution (p = 0.03).
3.1.2. Acceptability of the Original Formulations of Memantine
As the barycenter of all the 25 evaluations of the coated tablet was assigned to the “positively
accepted” profile, together with 100% of the surrounding confidence ellipses, this formulation tended
to be considered as accepted (see Figure 1). Although the barycenter of all the 60 evaluations of oral
solution was assigned to the “positively accepted” profile, a significant part of the confidence ellipses
was assigned to the “negatively accepted” profile. These results highlight that in the whole population,
regardless of patient characteristics, the oral solution was less well accepted than the coated tablet
which presumably masked the aversive taste of the API.
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3.1.3. Sex Differences
In men, both formulations tended to be similarly accepted, the confidence ellipses of the coated
tablet and the oral solution were overlapping. Conversely, the oral solution could not be considered as
accepted in women, while the coated tablet tended to be classified as such (Figure 2). There were no
significant differences between the groups of patients compared for both sexes, with the exception
of more frequent polypharmacy in the women treated by tablet than in those treated with the oral
solution (Table 1).
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Table 1. Characteristics of the patients treated with the original formulations of memantine (Ebixa®).
Patient Characteristics
Women Men
Coated
Tablet
(n = 15)
Oral
Solution
(n = 39)
Coated
Tablet
(n = 10)
Oral
Solution
(n = 21)
Age (Years)
[65, 75[ 1 (7) 1 4 (10) 0 (0) 3 (14)
[75, 85[ 5 (33) 11 (28) 3 (30) 8 (38)
[85, 95[ 9 (60) 19 (49) 7 (70) 10 (48)
[95, 104] 0 (0) 5 (13) 0 (0) 0 (0)
Statistical Test 0.642 (F) 2 0.557 (F)
Disabilities
Swallowing disorder 2 (13) 5 (13) 0 (0) 3 (14)
Statistical Test 1 (F) 0.533 (F)
Muscular or rheumatologic disorders of the upper limbs 2 (13) 5 (13) 1 (10) 3 (14)
Statistical Test 1 (F) 1 (F)
Cognitive impairment 15 (100) 39 (100) 10 (100) 21 (100)
Statistical Test 1 (F) 1 (F)
Medicine Exposure
Already taken 15 (100) 39 (100) 10 (100) 21 (100)
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Table 1. Cont.
Patient Characteristics
Women Men
Coated
Tablet
(n = 15)
Oral
Solution
(n = 39)
Coated
Tablet
(n = 10)
Oral
Solution
(n = 21)
Number of Prescribed Medicines per Day
[1–5[ 0 (0) 0 (0) 1 (10) 0 (0)
[5–10[ 4 (27) 24 (62) 3 (30) 8 (38)
≥10 11 (73) 15 (38) 6 (60) 13 (62)
Statistical Test 0.033 (F) 0.490 (F)
1 number and percentage: n (%); 2 F: Fisher’s Exact Test p-value.
3.2. Aversiveness Study in Animals
3.2.1. Aversiveness of Test Solutions
All preparations were assessed by 10 male and 10 female rats, both placebo and the original oral
solution of memantine. They were perceived as more aversive than water as indicated by a significant
reduction in lick number (Table 2).
Table 2. Non-parametric statistical testing to compare lickometer results between test solutions.
Test Solutions Water Ebixa Ebixa 3FD Ebixa 9FD Ebixa 27FD Placebo Placebo 3FD Placebo 9FD
Water NA <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Ebixa <0.001 NA 0.013 <0.001 <0.001 <0.001 <0.001 <0.001
Ebixa 3FD <0.001 0.025 NA 0.048 <0.001 <0.001 <0.001 <0.001
Ebixa 9FD <0.001 <0.001 0.048 NA <0.001 <0.001 <0.001 <0.001
Ebixa 27FD <0.001 <0.001 <0.001 <0.001 NA <0.001 <0.001 <0.001
Placebo <0.001 <0.001 <0.001 <0.001 <0.001 NA 0.44 0.14
Placebo 3FD <0.001 <0.001 <0.001 <0.001 <0.001 0.44 NA 0.44
Placebo 9FD <0.001 <0.001 <0.001 <0.001 <0.001 0.14 0.33 NA
Males vs.
Females 0.12 <0.001 0.35 0.008 0.032 <0.001 <0.001 <0.001
Results of post-hoc analysis carried out with Gao et al.’s non-parametric multiple test [21] to compare lickometer
results between Ebixa® (pure, at 3-, 9-, and 27-fold dilutions) and drug-free solutions (deionised water, and “placebo”
and its dilutions containing excipients alone), as well as any observed differences between the males and females for
each solution tested (p < 0.05 may be considered as significative).
The number of licks for each dilution of the original oral solution of memantine were significantly
different from each other (Table 2), while no significant differences were observed between the lick
numbers measured for the placebo formulation or any of its dilutions (Table 2). Lastly, the lick number
of all preparations of the original oral solution of memantine—unadulterated and diluted forms—were
significantly lower than those of placebo (Table 2), demonstrating the aversiveness of memantine
hydrochloride alone.
All test solutions of the original oral solution of memantine were classified as highly
aversive/untolerated (lick inhibition greater than 75%), except the solution diluted 27 times which was
classified as aversive/untolerated (lick inhibition in the range of 51%–75%). All the placebos were well
tolerated (lick inhibition <30%).
3.2.2. Sex Differences
No significant differences were observed between male and female rats for water (p = 0.12).
However, all other formulations yielded significantly different lick numbers among male and female
rats (Table 2), with the exception of the 3-fold diluted original oral solution of memantine, where no
significant difference was observed (p = 0.35); see Figure 3. Lick counts were consistently higher in
males for all samples.
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4. Discussion
These results demonstrated in the older population that palatability influences acceptability.
Although oral solutions are often assumed to be better adapted dosage form for this ageing population,
coated tablets have proven to be better accepted in this case. Subsequent sub-population analyses
of patient characteristics highlighted that sex was an important factor in memantine hydrochloride
acceptability. For men, no differences were observed between the oral solution and the tablet (positively
accepted), but the results were significantly different among women for whom the oral solution was
classified “negatively accepted.”
The characteristics of the women treated with the tablets versus those treated with the oral solution
(Table 2) were explored to better understand this result, revealing only that the number of medicines
prescribed per day was statistically different between the two groups. As those women taking the
oral solution had been prescribed significantly fewer medicines, it would be difficult to consider that
receiving more than 10 treatments per day could increase patient acceptability. As patient characteristics
did not provide any explanation for this difference in acceptability, product characteristics were explored.
Ingestion of the oral solution imposes a direct exposure of the mouth to the dissolved API, whereas
the tablet coating provides a physical barrier between the API and the patient’s taste buds [22]. Thus,
it is hypothesized that poor acceptability of the oral solution of memantine hydrochloride may have
been driven by a palatability issue. While it is well known that palatability optimization of oral
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solutions of an aversive API is challenging, it was surprising to observe such a gap in acceptability
between women and men. For these reasons we further investigated this using the BATA model to
compare male and female rats. After having confirmed that the memantine hydrochloride was highly
aversive/untolerated for rats in general, we also observed that it was significantly more aversive for
female rats than for males.
A recent systematic review focused on acceptability assessment of oral formulations among
children and older adults identified that only 17 studies have been included in the analysis of [23]. Even
fewer acceptability studies have been conducted in older populations, to the best of our knowledge
this is the first study that reveals a sex difference in medicine acceptability.
It would have been interesting to explore further sub-population analyses, but the discontinuation
of memantine hydrochloride subsidizing in France in August 2018 for efficacy and safety reasons [24]
prohibits further data collection in France. Nonetheless, a substantial number of patients were included
in this study, with a low heterogeneity of evaluations within each group. All of the observations
included in the analysis were performed in hospitals or nursing homes, while observations of older
home dwelling patients are lacking from these analyses. If we consider that the cognitive functions are,
per definition, more altered for institutionalized patients, we do not think that the aversiveness for
memantine hydrochloride could be lower in ambulatory treated women, but sensitivity to bitterness
could be higher for ambulatory men. However, to verify this assumption recruitment would have to
include other countries for the aforementioned reason.
The BATA model results are also of interest with regards to the excipients: the “Placebo” solution
presented a greater difference of aversiveness between male and female rats than the memantine
hydrochloride solution itself. The excipients of the original oral solution of memantine are 10% sorbitol
and potassium sorbate in purified water. At least one of these appears to be aversive for the female
rats but not for the males. Unfortunately, the experimental design did not allow for each ingredient to
be screened separately. However, sex differences in sugar preference have previously been discussed
in the literature. One of the studies testing the taste preference for glucose or saccharine solutions
demonstrated that female rats were more attracted to sweetness in oral solutions than males [25].
Similar results have been reported in other conditions with food [26]. However, in contrast to bitterness,
results related to sweetness and sex seem to be more difficult to extrapolate from this model to human
behavior. Effectively, a sensory study in human subjects [27] identified a difference of optimal sweetness
level depending on the sex, 20% sucrose for male and 10% for female, but the results of this study
also showed that the optimal level of sucrose decreased with age from 20% to 10%. Concerning the
second excipient, potassium sorbate is considered to be have a neutral taste [28]. Thus, although
it is unlikely to be the aversive factor in our drug free solutions as they were freshly made daily,
under some conditions the degradation of this molecule could generate a bitter taste [29] and even a
characteristic geranium taste [30]. To better understand their potential role in aversiveness, further
relevant investigations should be conducted.
Nevertheless, sex differences appear to be an important factor to consider for dosage form
prescription. Unpublished observations on oral liquid solution in older populations and preliminary
findings on antibiotics formulations with distinct flavors have highlighted such a sex difference due to
excipient compositions.
The human study and animal model demonstrated that the unpleasant taste of the oral solution
was a major issue in both women and female rats. The BATA tool generates relevant results in an
objective and quantitative manner for the early prediction of aversiveness during drug development.
Here, these results were consistent with the observations analyzed by CAST, which offers a suitable
scoring tool for the evaluation of medicine acceptability in real-life conditions.
Despite reported observations that Alzheimer disease worsens taste and smell impairments in the
older population [31], this study has demonstrated that palatability issues remain an important driver
of acceptability in these targeted patients. Palatability should therefore be more broadly monitored
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during drug development by manufacturers and regulators even when the intended to treat population
is an older one.
These findings confirm that acceptability is determined by both users and products
characteristics, and underline the need for a better understanding of patients’ needs to promote
personalized prescription.
5. Conclusions
This study on a particular Alzheimer’s disease treatment highlighted acceptability issues with the
original oral solution of memantine (Ebixa®) driven by palatability. Indeed, according to CAST the
coated tablet, which created a physical barrier between the memantine hydrochloride and taste buds,
was well accepted in the older population, while this appeared not to be the case for the oral solution.
Furthermore, the BATA model objectively confirmed the aversiveness of this formulation. Exploring
sex differences, consistent findings from both human studies and animal models highlighted a higher
sensitivity of the females to this unpalatable oral formulation as the proposed cause for suboptimal
acceptability. These findings showed that palatability of oral liquid pharmaceutical formulations
can remain a key aspect of acceptability in the older population, especially in women. Therefore,
formulation scientists and the pharmaceutical industry should consider taste masking as a key quality
attribute of all products developed for the older population. Furthermore, healthcare professionals
should consider the specific features of their patients to prescribe a medicine with the best adapted
characteristics to reach an optimal acceptability.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/8/368/s1,
Table S1: Randomization schedule for testing days 1 and 2, Table S2: Demographic characteristics of the patients,
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